Vigil Neuroscience — Technical Presentation (December 2022)
127 slides from Vigil Neuroscience's technical presentation, Dec 6, 2022
Slide 1: ALSP KOL Event
Vigil Neuroscience, Inc. ALSP KOL Event December 6, 2022 © Vigil Neuroscience, Inc. 2022. All rights reserved. Exhibit 99.1
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS 2 © Vigil Neuroscience, Inc. 2022. All rights reserved. This presentation contains “forward-looking statements,” which are made pursuant to the safe harbor provisions of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Any statem
Slide 3: Introduction & Corporate Overview
Introduction & Corporate Overview Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 4: Vigil 2022 ALSP Key Opinion Leader Event – Agenda
Vigil 2022 ALSP Key Opinion Leader Event – Agenda 8:30 – 10:00 AM Opening Remarks & Corporate Overview Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience, Inc. What is ALSP? David S. Lynch, MD, PhD Consultant Neurologist National Hospital for Neurology & Neurosurgery, Quee
Slide 5: Vigil Neuroscience
Vigil Neuroscience Vigil Neuroscience is a clinical-stage microglia-focused therapeutics company Our purpose: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells We are utilizing the tools of modern neuroscience drug developm
Slide 6: Vigil's Mission: Restoring Microglial Vigilance
Vigil’s Mission: Restoring Microglial Vigilance to Create Disease-Modifying Treatments for Neurodegenerative Diseases Discovering and developing novel therapeutics designed to leverage microglial biology breakthroughs that activate and restore microglial function Precision-based development strategy
Slide 7: Vigil's Precision Medicine Strategy
Vigil’s Precision Medicine Strategy to Target Broad Range of Neurodegenerative Diseases First Indication Rare Microgliopathy Data Driven Expansion in Other Rare Microgliopathies Pipeline Candidates for Genetically Defined Subpopulations in Common Indications Further Expansion into Broader Population
Slide 8: Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities
Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities ALSP: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia TREM2 mAb in Development for ALSP: VGL101 Small Molecule TREM2 Agonist in Development for Larger Indications The ONLY targeted drug candidate in developm
Slide 9: Our Pipeline
Our Pipeline Vigil Has Exclusive Rights to All Programs Discovery Preclinical Phase 1 Alzheimer’s Disease VGL101 Healthy Volunteer SAD & MAD Phase 1 Trial (interim data announced)* Healthy Volunteer IND-Enabling Studies Small Molecule TREM2 Agonist Program Phase 2 Preclinical PoC Evaluation Other Le
Slide 10: VGL101 – Human mAb Agonist of TREM2
VGL101 – Human mAb Agonist of TREM2 with a Compelling Profile High TREM2 selectivity; induces microglial genes with sub-nanomolar potency Preclinical proof of concept in human iPSC derived microglia Favorable safety & tolerability profile with linear, dose proportional PK in HVs Dose dependent, robu
Slide 11: Summary of Interim Topline VGL101 Phase 1 Data in Healthy Volunteers
Summary of Interim Topline VGL101 Phase 1 Data in Healthy Volunteers* *As of October 7, 2022, and includes doses up to 40 mg/kg SAD and 20 mg/kg MAD © Vigil Neuroscience, Inc. 2022. All rights reserved. Demonstrated a favorable safety and tolerability profile Pharmacokinetics showed linear, predicta
Slide 12: Driving ALSP Awareness via Stakeholder Engagement
Driving ALSP Awareness via Comprehensive Stakeholder Engagement Focused on increasing accurate & timely diagnosis Building Strong Foundation with Patient Advocacy Groups (PAGs) Established relationships with regional & global PAGs across relevant neurodegenerative diseases (including ALSP, leukodyst
Slide 13: Building Toward Success in ALSP Clinical Development
Building Toward Success in ALSP Clinical Development Retrospective Biomarker & Chart and Systematic Literature Reviews Phase 1* SAD/MAD Trial Patient & KOL Engagement Natural History Study Phase 2** Proof-of-Concept Trial Phase 3** Trial © Vigil Neuroscience, Inc. 2022. All rights reserved. *Involvi
Slide 14: Featured Key Opinion Leaders
Featured Key Opinion Leaders David S. Lynch, MD, PhD Consultant Neurologist, National Hospital for Neurology & Neurosurgery, Queen Square & UCL Institute of Neurology, London, U.K. Clinical Lead, Adult Inherited White Matter Disorders Highly Specialist Service, NHS England Troy Lund, MSMS, PhD, MD,
Slide 15: What is ALSP?
What is ALSP? David S. Lynch, MD, PhD Consultant Neurologist National Hospital for Neurology & Neurosurgery, Queen Square & UCL Institute of Neurology, London Clinical Lead Inherited White Matter Disorders Highly Specialist Service, NHS England
Slide 16: Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) An inherited neurodegenerative disorder Rare and under-recognized Primarily causing degeneration of brain white matter (i.e., an ‘Inherited White Matter Disorder’ or ‘leukoencephalopathy/leukodystrophy’) The hallmark axo
Slide 17: ALSP Alternative Names
ALSP Has been known by a number of alternative names, largely hangovers from the era before MRI and genetics were widely available First described as pigmentary orthochromatic leukodystrophy (POLD) in 1936 Later, the name hereditary diffuse leukoencephalopathy with spheroids (HDLS) became more widel
Slide 18: ALSP Symptoms
ALSP Symptoms A progressive, neurodegenerative disorder Demyelination (destruction) of white matter in the brain has widespread and devastating effects Symptoms can be similar to more widely recognized diseases Cognitive symptoms: similar to Frontotemporal Dementia (FTD) Motor symptoms: similar to P
Slide 19: ALSP Symptoms
ALSP Symptoms Symptoms most often develop in the 40s but the range is wide (18–86 years) Cognitive and ‘neuropsychiatric’ symptoms are often first to emerge Word Finding Difficulty Executive Dysfunction Insomnia Agitation Depression Confusion Memory Loss
Slide 20: ALSP Symptoms
ALSP Symptoms Personality change New anxiety, depression Difficulty in work, decision making Inappropriate behavior Memory problems Word finding and speech problems Cognitive As the Disease Progresses, Symptoms Multiply
Slide 21: ALSP Symptoms
ALSP Symptoms Gait and balance problems Stiffness, slowness of movement Incoordination, tremor Swallowing and speech difficulty Motor As Symptoms Progress, Patients Become More Immobile to the Point of Being Bedbound and Totally Dependent for Care
Slide 22: ALSP Patient Video
ALSP Patient Video
Slide 23: Relentlessly Progressive ALSP
Relentlessly Progressive ALSP Progression 75% survival for approximately 3 years, 50% for 5 years, 25% for 10 years and < 5% for 30 years Papapetropoulos et al. American Academy of Neurology Conference 2022
Slide 24: Symptom Overlap with Other Diseases (Misdiagnosis)
Symptom Overlap with Other Diseases (Misdiagnosis) Frontotemporal Dementia (FTD) Alzheimer Disease (AD) Primary Progressive Multiple Sclerosis (PPMS) Parkinson Disease (PD) Other inherited white matter disorders Mostly Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoence
Slide 25: ALSP Magnetic Resonance Imaging
ALSP Magnetic Resonance Imaging Normal MRI ALSP D. Lynch unpublished data
Slide 26: ALSP Typical Imaging
ALSP Typical Imaging A B C D E F G F Wade & Lynch: Handbook of Clinical Neurology, Inherited White Matter Disorders
Slide 27: Misdiagnosis
Misdiagnosis D. Lynch unpublished data ALSP Progressive MS The Direction of Misdiagnosis is the Failure to Recognize ALSP
Slide 28: Neuropathology – Axonal Swellings and Pigmented Glia
Neuropathology – Axonal Swellings (Spheroids) and Pigmented Glia Lynch DS et al, Journal of Neurology, Neurosurgery & Psychiatry 2016.
Slide 29: Epidemiology
Epidemiology Inherited white matter disorders (IWMD) are rare but recognition is growing due to: Better access to genetics Widespread availability of imaging Increased understanding of phenotypes, particularly in adults UK has just established first national specialist service for IWMD >300 Reported
Slide 30: Epidemiology – at Least 10–15% of IWMDs
Epidemiology – at Least 10–15% of IWMDs
Slide 31: Latest Unpublished Data Queen Square & UCL
Latest Unpublished Data Queen Square & UCL Institute of Neurology ALSP 13/76 Most Recent IWMD Diagnoses (17%) Charlie Wade, UCL, 2022, unpublished Number of Confirmed/Diagnosed Cases
Slide 32: Genetics
Genetics Autosomal dominant inheritance Multiple generations can be affected Children and siblings of a patient are at 50% risk of being affected Kraya et al, Mol Genet Genomic Med 2019 De novo cases also occur (children remain at 50% risk) Penetrance is incomplete but very high
Slide 33: Genetics: Causative Gene Identified in 2011
Genetics In 2011, the Causative Gene Was Identified
Slide 34: CSF1R
CSF1R Colony stimulating factor-1 receptor gene Encodes a cell surface receptor highly expressed on myeloid cells including brain microglia Microglia are critically important immune cells with diverse functions ALSP is a microgliopathy
Slide 35: CSF1R Mutations
CSF1R Majority of mutations affect tyrosine kinase activity → loss of function No genotype/phenotype correlation Tian et al. Transl Neurodegener 2019
Slide 36: CSF1R Activation
CSF1R Activation Ligand binding leads to Receptor homodimerization Tyrosine kinase domain (TKD) autophosphorylation Downstream signaling for microglial proliferation, survival and differentiation Inhibition of CSF1R rapidly depletes the brain of microglia Elmore et al Neuron 2014; Rademakers et al,
Slide 37: CSF1R LoF Leads to Microglial Loss and Dysfunction in ALSP
CSF1R LoF Leads to Microglial Loss and Dysfunction in ALSP Konishi & Kiyama Front. Cell. Neurosci. 2018; Kempthorne et al. Acta Neuropathologica. 2020 Microglia Numbers Based on IBA-1 Staining Microglial Phenotype Based on Gene Expression 1 1 1. HDLS: hereditary diffuse leukoencephalopathy with sphe
Slide 38: Microglial Loss and Dysfunction in ALSP
Kempthorne et al. Acta Neuropathologica. 2020 Microglial Loss and Dysfunction in ALSP 1. HDLS: hereditary diffuse leukoencephalopathy with spheroids – previously used to describe ALSP; GM: grey matter; WM: white matter 1
Slide 39: Genetic Diagnosis
Genetic Diagnosis The cost of sequencing has plummeted in recent years Diagnostic rates for genetic disorders are improving Most clinicians are using panels of many genes Diagnosis can be made even without a high suspicion of ALSP
Slide 40: ALSP Diagnosis
ALSP Diagnosis Referrals come from a variety of sources Cognitive clinics MS clinics Movement Disorders Clinical/Neurogenetics Neuroradiology
Slide 41: Summary
Summary ALSP is rare but under-recognized It is a devastating neurodegenerative disorder ALSP is a microgliopathy Diagnostic rates are rapidly improving due to advances in genetic technology
Slide 42: ALSP History and Diagnosis
ALSP History and Diagnosis Christina Sundal, MD, PhD CEO NeuroClinic Norway Senior Consultant University Hospital, Oslo, Norway Department of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
Slide 43: Background
Background Encompasses a heterogenous group of disorders that predominantly affect the brain’s white matter (WM), regardless if myelin damage is primary or secondary, and irrespective of a molecular cause (Van der Knaap) Leukoencephalopathy Leukodystrophy Neuroaxonal Degeneration (Leuko-white, Dystr
Slide 44: Hereditary Leukoencephalopathies
Hereditary Leukoencephalopathies ALSP Pelizaeus 1885 Krabbe 1913 ALD 1910 MLD 1933 Alexander 1949 NHD 1970 HDLS 1984 LBSL 2003 HDLS type 2 2011 Merzbacher 1909 Metachromatic Staining 1910 “Le type tardif de la leucodystrophie progressive familial” 1936 Canavan 1949 GAN 1977 ADLD 1984 VWM 1993 ? ? ?
Slide 45: Adult Hereditary Leukoencephalopathies
Adult Hereditary Leukoencephalopathies Leukodystrophies: Pelizaeus-Merzbacher disease (PMD) Adrenoleukodystrophy (ALD) Metachromatic Leukodystrophy (MLD) Krabbe disease ALSP Nasu-Hakola disease STROKE-LIKE Symptoms/Small Vessel Disease Fabrys Cerebral Autosomal Dominant Arteriopathy with Sub-cortica
Slide 46: Swedish ALSP Family
Swedish ALSP Family 166 Individuals 6 Generations: born 1855–1990 15 Affected: 2 New Cases 4 Cases healthy
Slide 47: Families Studied
14 Families Studied ALSP United States Norway Germany Scotland Inclusion criteria Clinical MRI Neuropathology Blood Dr. Dennis Dickson, neuropathologist at the Mayo Clinic confirmed the presence of axonal spheroids embedded in the abnormal white matter, consistent with the original Swedish HDLS/ALSP
Slide 48: ALSP Misdiagnosed
ALSP MISDIAGNOSED Rademakers et al . Nat Genet. 2012
Slide 49: ALSP Misdiagnosed
ALSP Misdiagnosed: Multiple Sclerosis, Alzheimer’s Disease, CADASIL, Atypical Parkinson’s Disease, Neuromyelitis Optica, other neurodegenerative disorders Average age of symptom onset: 44 years (range: 36-52) Average disease duration: 6 Years (range: 3-11) Average age of death: 48 years (range: 40-6
Slide 50: CSF1R Mutation
CSF1R CSF1R Mutation Rademakers et al . Nat Genet. 2012
Slide 51: Cross Talk: CSF1R-TREM2/DAP12
Cross Talk: CSF1R-TREM2/DAP12 Sundal C. Hereditary Diffuse Leukoencephalopathy with Spheroids ; Insights into an adult onset neurodegenerative disease , PhD dissertation 2013
Slide 52: ALSP Carrier/Patient Journey
Mild Symptomatic Clinical diagnosis Genetic testing and disease management depends on family history 31% of carriers are diagnosed correctly at this stage Severely Symptomatic Patients become bedridden and terminally ill Moderate Symptomatic Rapid symptoms progression Patients eventually become inca
Slide 53: Diagnostic Criteria for ALSP
Diagnostic Criteria for ALSP Age <65 Years Sporadic Hereditary Brain MRI CSF1R Gene Cognitive impairments Pyramidal signs Parkinsonism Epilepsy White matter lesion No brain stem atrophy Absent grey matter signal intensity (SI) No enhancement >2 Clinical Signs
Slide 54: ALSP Clinical Course
ALSP Clinical Course Psychiatric disorders Cognitive impairments Behavioral/Personality changes Dementia Paresis Parkinsonian signs/Movement disorders Seizure End stage: urinary incontinence, dysphagia/aphasia, weight loss Death: Aspiration pneumonia Multisystem Encephalopathy
Slide 55: What Do You See on the Brain MRI?
What Do You See on the Brain MRI? Adult-onset Leukoencephalopathy with Axonal spheroids and Pigmented Glia (ALSP) X-linked Adrenoleukodystrophy (X-ALD) Metachromatic Leukodystrophy (MLD) Krabbe disease Alexander disease Adult-onset Autosomal Dominant Leukodystrophy (ADLD) Vanishing white matter (VWM
Slide 56: ALSP MRI Algorithm
Frontal/Parietal WML Occipital WML Periventricular WML Brain Stem Atrophy Diffuse Cerebral WML Multi-Focal WML MLD ALSP ALD ALD Krabbe ALSP MLD Krabbe LBSL LBSL Alexander ADLD End-Stage of all WMD ALSP MRI Algorithm Prominent T2-hyperintensities Relative to Grey Matter Hypomyelination WML: white mat
Slide 57: MRI of ALSP
MRI of ALSP Sundal C et al. J Neurol Sci. 2012
Slide 58: MRI's Role in Diagnosis and ALSP Research
MRI’s Role in Diagnosis and ALSP Research All WML bilateral, asymmetric; predominantly frontal Grey matter signal intensity changes absent No brain stem atrophy Corticospinal tracts involved later No enhancement Minimal cerebellar pathology Sundal C et al. Neurology. 2012
Slide 59: Qualitative MRI Measures
Qualitative MRI Measures White Matter Signal Max Score Frontal 7 Parietal 7 Temporal 7 Occipital 7 Corpus Collosum 6 Projection fibers 6 Brainstem 1 Cerebellum 1 WML Score 42 Basal Ganglia 1 Thalamus 1 Deep Gray Matter 2 Atrophy Max Score Frontal 2 Parietal 2 Temporal 2 Occipital 2 Central 2 Corpus
Slide 60: MRI Severity Score
MRI Severity Score Based on 15 patients with CSF1R mutations in 2012 Score: 4 (Figure A) Stable disease course Mild Disease (Score 1-6; n = 1) Mean Score: 12.7 [range 10-15] (Figures B, E & F Mean disease duration of 6.7 years (range, 5.0 -9.8) Moderate Disease (Score 7-15; n = 4) Mean Score: 20.5 [
Slide 61: Quantitative MRI Measures
Quantitative MRI Measures Smith et al Neuroimage (2002); Griffanti et al Neuroimage (2016) Disease burden on MRI can be quantified by measures of brain region volume e.g. Frontal, parietal, corpus callosum, ventricle and lesion volumes
Slide 62: Quantitative and Qualitative MRI Measures
Quantitative and Qualitative MRI Measures MRI Severity Score: 17 Patient #1 MRI Severity Score: 27 Patient #2 Lesion volume: 26 mL Lesion Volume: 81 mL Vigil retrospective chart review data
Slide 63: Longitudinal MRI Follow-up on CSF1R Mutation Patient
Longitudinal MRI Follow-up on CSF1R Mutation Patient Every 6 months Sundal C et al. Neurology. 2012
Slide 64: MRI Characteristic Pattern
MRI Characteristic Pattern MRI Summary Disease onset before 45 years Female WMLs extending beyond the frontal regions (MRI Scoring System & volumetric analysis) MRI severity score greater than 15 points Most recognizable in the middle stages of the disease Indicators of Progressive Disease MRI volum
Slide 65: NfL as Disease Biomarker for ALSP
NfL as Disease Biomarker for ALSP Controls: healthy individuals; ALSP : symptomatic ALSP patients; MS: multiple sclerosis patients; Mutation Carriers: pre-symptomatic individuals with CSF1R mutations; **p < 0.005, ***p < 0.0005, ****p <0.0001 Serum NfL CSF NfL Serum NfL CSF NfL Serum NfL Hayer et al
Slide 66: Combining the Results
Disorder ALSP Neurodegenerative disorders MRI Distinct distribution Depending on disorder CSF NfL ééé Depending on disorder Neuropathology Many Spheroids Thin layer of Myelin surrounding some Spheroids Depending on disorder CSF1R gene mutation Yes No Combining the Results Primary Neuroaxonal Degener
Slide 67: Summary on ALSP Diagnosis
Summary on ALSP Diagnosis Clinical symptoms to provide clues MRI to guide diagnosis CSF1R genetic testing to confirm diagnosis
Slide 68: Current Challenges of Correctly Diagnosing ALSP
Current Challenges of Correctly Diagnosing ALSP Awareness of adult onset hereditary leukoencephalopathies Leukodystrophies/Neuroaxonal dystrophies (degeneration) MRI: Pattern recognition Gene testing: CSF1R
Slide 69: Differential Diagnosis to ALSP
Differential Diagnosis to ALSP Screen for CSF1R Gene ALD Krabbe Disease VWM ADLD FTD AD CBD PSP PML PPMS CJD CADASIL ADVL SVD LBSL NPH NHD MLD Clinical Similarities Both Clinical & MRI Similarities MRI Similarities AD: Alzheimer’s Disease; CBD: Corticobasal Degeneration; PSP: Progressive Supranuclea
Slide 70: Phenotypic Variation
Phenotypic Variation Parental Environment Parental Genotype Phenotype of Adult Individual Imprinting DNA methylation Chromatin Structural changes
Slide 71: Misdiagnosis of ALSP
Misdiagnosis of ALSP Awareness of ALSP
Slide 72: Misdiagnosis of ALSP
Misdiagnosis of ALSP 3 ALSP Cases 1.3% ALSP? 149 *Ann Neurol. 2011;70:437–444. **Arch Neurol. 2009; 66(9):1139–1143 * **
Slide 73: Misdiagnosis of ALSP
Misdiagnosis of ALSP Misdiagnosis highlights importance of early genetic testing and increased disease awareness Rate of initial misdiagnosis significant in ALSP Accurate initial diagnosis is observed in only 31.5% of ALSP patients Misdiagnosis involved broad spectrum of neurodegenerative, neuroimmu
Slide 74: How Can We Improve ALSP Diagnosis
How Can We Improve ALSP Diagnosis Definitive diagnosis through genetic testing for CSF1R mutations Need to increase awareness of ALSP to drive earlier referrals of potential patients for definitive genetic testing
Slide 75: Overall Conclusion on ALSP
Distinct disease entity Divergent clinical courses Initial symptoms Later symptoms CSF1R gene mutation MRI – pattern recognition Advanced neuroimaging Primary neuroaxonal degeneration Misdiagnosed disease Overall Conclusion on ALSP
Slide 76: ALSP: Devastating Adult-onset Neurodegenerative Disease
ALSP: Devastating Adult-onset Neurodegenerative Disease Wide Geographic Distribution Diagnostic Clues CSF1R-related ALSP
Slide 77: The Swedish ALSP Research Team
The Swedish ALSP Research Team:
Slide 78: Thank You
ee THANK YOU Fey meee The Sahlgrenska Adademy. 78 university oF GoTHENBURG
Slide 79: ALSP Treatment and Unmet Medical Need
ALSP Treatment and Unmet Medical Need Troy Lund, MSMS, PhD, MD, FAAP Leukodystrophy Center of Excellence Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy University of Minnesota, A NORD Rare Disease Center of Excellence
Slide 80: Current ALSP Treatment Options
Current ALSP Treatment Options No approved therapies for ALSP Most off-label treatments focus on symptom alleviation Minimal to modest QoL improvements No effect on underlying disease process or progression Hematopoietic stem cell transplant (HSCT) has been provided as a treatment option by very few
Slide 81: HSCT Case Report in ALSP – Patient 1
44 year-old female CSF1R mutation: Q642X Memory problems, disinhibition, “early onset dementia” Noted on exam: patient showed intermittent tongue and lip movements, resembling tics MRI showed confluent, frontal-predominant white matter T2 hyperintensities Other past medical information: History of d
Slide 82: Patient 1: Post-HSCT Complications with Cognitive Worsening
Unrelated donor (URD) marrow (HLA match = 12/12) Transplant related morbidity (TRM): mild gastrointestinal graft-vs-host disease (GvHD) and cystitis Potential GCSF neurologic exacerbations? Through 27 months post HSCT: Went to transition care unit for aggressive rehab and nutrition Worsening of cogn
Slide 83: Patient MRI: Post-HSCT White Matter Lesion and Ventricular Increase
Patient 1 MRI: Post-HSCT White Matter Lesion and Ventricular Increase 3 Years Post HSCT PRE HSCT
Slide 84: HSCT Case Report in ALSP – Patient 2
46 year-old female CSF1R mutation: W893R With rapidly progressively gait deterioration over a 4-month period, resulting in loss of employment Neurological examination showed global hyperreflexia, parkinsonism, and gait impairment requiring a wheelchair Neuropsychological evaluation showed impairment
Slide 85: Patient 2: Post-HSCT Stabilization
Received matched sibling bone marrow Neuropsychological evaluation 4 months post-HSCT showed declines in some aspects of attention, executive function, and processing speed but with improvements in verbally mediated tasks, including naming and fluency Neurological examination at 9 months post-HSCT w
Slide 86: Patient 2: Post-HSCT MRI Stabilization
Patient 2: Post-HSCT MRI Stabilization 2 Years Post HSCT PRE HSCT
Slide 87: HSCT Case Report in ALSP – Patient 3
44 year-old female CSF1R mutation: p.R782H 2 years of progressive personality changes resulting in employment termination Associated with memory decline, perseveration, spelling difficulties, and falls Also, patient was losing objects and having difficulty clothing herself An acute episode of langua
Slide 88: Patient 3: Post-HSCT Neurological Decline
Received matched sibling bone marrow Post-HSCT complications: GvHD of the gut, acute kidney injury, strep mitis of the blood, pulseless electrical activity (cardiac arrest) Patient was resuscitated and extubated but quickly deteriorated from a neurological standpoint Day 81 post-HSCT – brain MRI sho
Slide 89: Patient 3: Post-HSCT White Matter Lesion Increase
Patient 3: Post-HSCT White Matter Lesion Increase 2 Months Post HSCT PRE HSCT
Slide 90: HSCT Case Report in ALSP – Patient 4
41 year-old male CSF1R mutation: NM_005211.3; c.2381T>C (p.Ile794Thr) 1-2 years with some lower leg weakness, some memory problems, and losing track of conversation His wife filled in many of the gaps and answered many of the questions 1-2 years of depression and anxiety He was losing his temper eas
Slide 91: Patient 4: Post-HSCT Mobility Gain but Cognitive Decline
8/8 URD, 100% engrafted Complications include pseudomonas pneumonia, Burkholderia infection, sinusitis, weight loss requiring G-tube, possible idiopathic pneumonia syndrome (IPS) Progressive dementia Became very weak and lost a lot of physical conditioning After 1-year post-HSCT, patient regained we
Slide 92: Patient 4: Post-HSCT White Matter Lesion Increase and Atrophy
Patient 4: Post-HSCT White Matter Lesion Increase and Atrophy 10 M Post HSCT PRE HSCT
Slide 93: Case Reports from Limited HSCT in ALSP
These case reports represent a broad spectrum of post-HSCT outcomes on clinical measures and MRI, and show that: HSCT appears to have variable impact on ALSP which is yet to be fully characterized Risks of HSCT come from being an adult and possibly poor mobility Post-HSCT disease progression can be
Slide 94: High Unmet Need for ALSP Disease Modifying Treatments
Symptomatic treatments provide transient and limited benefit to ALSP patients Allogeneic HSCT: Limited experience with HSCT Case reports show mixed outcomes HSCT in ALSP is associated with significant morbidity and mortality Main risks of HSCT come from being an adult and possibility poor mobility s
Slide 95: CSF1R Mutations Lead to Microglia Loss & Dysfunction in ALSP
CSF1R Mutations Lead to Microglia Loss & Dysfunction in ALSP Quantification of Microglia in Brain Regions Konishi & Kiyama Front. Cell. Neurosci. 2018; Kempthorne et al. Acta Neuropathologica. 2020 1. HDLS: hereditary diffuse leukoencephalopathy with spheroids – previously used to describe ALSP; WM:
Slide 96: VGL101 Rescued Microglial Viability under CSF1R Deficiency
VGL101 Rescued Microglial Viability under CSF1R Deficiency Inhibition by PLX5622 & Rescue by VGL101 **** **** **** **** ns Viability as % of Rescue Control A B C D F 120 40 20 0 100 80 60 E ns ** ** ** Viability as % of Vehicle Control 140 60 40 20 0 100 80 A B C E D 120 iMGL: human Induced pluripot
Slide 97: VGL101 Reduced Microglial Apoptosis under CSF1R Deficiency
VGL101 Reduced Microglial Apoptosis under CSF1R Deficiency Caspase 3/7 Activation as % of PLX5622 ns *** * *** 120 60 40 20 0 100 80 A B C D E iMGL: human Induced pluripotent stem cells (iPSC) derived microglia; PLX5622 – known small molecule inhibitor of CSF1R; P-values are as determined by Ordinar
Slide 98: VGL101 Restored Microglial Morphology under CSF1R Deficiency
VGL101 Restored Microglial Morphology under CSF1R Deficiency iMGL – human Induced pluripotent stem cells derived microglia; PLX5622 – known small molecule inhibitor of CSF1R Cell Eccentricity – degree of cellular processes emanating from longitudinally imaged human microglia, quantified by optical l
Slide 99: VGL101 as Potential Disease Modifying Therapy for ALSP via TREM2 Agonism
VGL101 demonstrated ability to restore microglia numbers and function in human microglia cultures (Larson et al. Keystone Symposium 2022) Represents a potential disease modifying therapeutic for ALSP with monthly IV administration Clinical trials are needed to show proof-of-concept, safety/tolerabil
Slide 100: Break
Break © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 101: ILLUMINATE Natural History Study in ALSP
ILLUMINATE Natural History Study in ALSP Spyros Papapetropoulos, MD, PhD Chief Medical Officer Vigil Neuroscience © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 102: Compelling Rationale for ALSP as Initial Indication for VGL101
Compelling Rationale for ALSP as Initial Indication for VGL101 Vigil’s VGL101 program is the first and only drug candidate in development in this indication seeking full engagement of patient and scientific community Opportunity to be first to achieve human PoC with a TREM2 agonist Orphan, under-rec
Slide 103: ALSP Natural History Study Design
ALSP Natural History Study Design The Illuminate Study Natural history study of ALSP patients with CSF1R gene mutation Sample size up to 36 subjects (global) Objectives: Characterize biomarkers & clinical measures of disease progression in ALSP Possibility for contemporaneous external comparator arm
Slide 104: ALSP Natural History Study – Current Status
ALSP Natural History Study – Current Status © Vigil Neuroscience, Inc. 2022. All rights reserved. Study Timeline: first patient enrolled in Q3 2021 Enrollment ongoing in US and ex-US Current Locations: US: Jacksonville, FL; Boca Raton, FL; San Francisco, CA; Englewood, CO Canada: London, Ontario Ger
Slide 105: Natural History Study – Interim Dataset
Natural History Study – Interim Dataset Interim data includes participants enrolled as of October 1, 2022 29 participants enrolled at 6 sites comprising 18 symptomatic and 11 prodromal* participants 18 participants completed 6-month MRI visit 9 symptomatic and 9 prodromal participants Clinical stage
Slide 106: Quantifying MRI Features of ALSP
Quantifying MRI Features of ALSP Brain Atrophy and White Matter Lesions Are Key Radiological Features of ALSP Disease Burden on MRI Was Assessed by Quantitative MRI Measures of Brain Region Volume Healthy ALSP © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 107: Greater Baseline Disease Burden for Symptomatic vs Prodromal Participants
Greater Baseline Disease Burden for Symptomatic vs Prodromal Participants Baseline volumetric MRI findings Greater Disease Burden Associated with Lower Brain Tissue Volume Prodromal (11) Symptomatic (16) 200 150 100 50 0 Frontal Parietal Corpus Callosum Volume (ml) © Vigil Neuroscience, Inc. 2022. A
Slide 108: Greater Baseline Disease Burden for Symptomatic vs Prodromal Participants
Greater Baseline Disease Burden for Symptomatic vs Prodromal Participants Baseline volumetric MRI findings Greater Disease Burden Associated with Higher Lesion and Ventricle Volume Volume (ml) 150 100 50 0 White matter lesion Ventricle Prodromal (11) Symptomatic (16/18*) * No. of symptomatic partici
Slide 109: Greater Disease Progression for Symptomatic vs Prodromal Participants at 6 Months
Greater Disease Progression for Symptomatic vs Prodromal Participants at 6 Months 6-month volumetric MRI findings Prodromal (9) Symptomatic (8) Disease Progression 3 -3 -6 -9 Frontal Parietal Corpus Callosum 0 % Change from Baseline Greater Disease Progression Based on Greater Reductions in Brain Ti
Slide 110: Greater Disease Progression for Symptomatic vs Prodromal Participants at 6 Months
Greater Disease Progression for Symptomatic vs Prodromal Participants at 6 Months 6-month volumetric MRI findings Disease Progression % Change from Baseline 20 10 5 0 White matter lesion Ventricle 15 Prodromal (9) Symptomatic (7/91) Greater Disease Progression Based on Greater Increases Lesion and V
Slide 111: Radiographic Progression Measurable at 6 Months – Case Example 1
Radiographic Progression Measurable at Month 6 Baseline Month 6 Case Example #1: 31 year | Male | CSF1R mutation | Symptomatic ALSP | MoCA at Baseline / 6 month: 15 / 12 Increased white matter lesion Increased atrophy Increased ventricular volume © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 112: Radiographic Progression Measurable at 6 Months – Case Example 2
Radiographic Progression Measurable at Month 6 Case Example #2: 37 year | Female | CSF1R mutation | Symptomatic ALSP | MoCA at baseline / 6 month: 15 / 9 Baseline Month 6 Baseline Month 6 Increased white matter lesion Increased ventricular volume Increased white matter lesion © Vigil Neuroscience, I
Slide 113: Fluid Biomarker Baseline Levels Altered in ALSP Individuals
Fluid Biomarker Baseline Levels Altered in ALSP Individuals sTREM2 sTREM2 Levels Comparable between Prodromal/Symptomatic and Healthy sCSF1R sCSF1R Levels Reduced in Prodromal/Symptomatic vs Healthy NfL NfL Levels Increased in Symptomatic Reflecting Active Neurodegeneration CSF Serum Healthy: health
Slide 114: Emerging ILLUMINATE Data Support IGNITE Design
Emerging ILLUMINATE Data Support IGNITE Design Symptomatic ALSP patients exhibit greater baseline disease burden based on MRI vs healthy and prodromal individuals Lower brain volume Greater white matter lesion and ventricular volumes Measurable MRI changes observed at 6 months indicating disease pro
Slide 115: VGL101 IGNITE Phase 2 Design & Objectives
VGL101 IGNITE Phase 2 Design & Objectives Spyros Papapetropoulos, MD, PhD Chief Medical Officer Vigil Neuroscience © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 116: VGL101 ALSP Phase 2 Open-label Proof-of-Concept Trial Design
VGL101 ALSP Phase 2 Open-label Proof-of-Concept Trial Design Screening VGL101 (12 months, IV administration) Follow up Study Population Patients with symptomatic ALSP related to CSF1R gene mutation Study Design Open-label, up to 15 patients Treatment Duration 12 months (with opportunity for further
Slide 117: VGL101 ALSP Phase 2 Patient Population
VGL101 ALSP Phase 2 Patient Population Key Clinical Inclusion Criteria Key Clinical Exclusion Criteria Documentation of a CSF1R gene mutation Clinical symptoms consistent with ALSP MRI findings consistent with ALSP Mild and early-moderate stages defined by cognitive and ambulation status Any neurolo
Slide 118: VGL101 ALSP Phase 2 Objectives & Outcomes
VGL101 ALSP Phase 2 Objectives & Outcomes AE: adverse event; ECG: electrocardiogram; MRI: magnetic resonance imaging; NfL: Neurofilament Light Chain Protein; sCSF1R: soluble colony-stimulating factor 1 receptor; CSF: cerebrospinal fluid; MoCa: Montreal Cognitive Assessment; CDR®+NACC-FTLD: Clinical
Slide 119: Closing Remarks
Closing Remarks Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 120: Unmet Need & Clinical Trial Readiness Support Development of VGL101 in ALSP
Unmet Need & Clinical Trial Readiness Support Development of VGL101 in ALSP ALSP is a rare devastating, progressive and fatal microgliopathy that is significantly under-recognized Significant portion of patients initially misdiagnosed with other neurodegenerative diseases Advances in MRI and genetic
Slide 121: Unmet Need & Clinical Trial Readiness Support Development of VGL101 in ALSP
Unmet Need & Clinical Trial Readiness Support Development of VGL101 in ALSP VGL101 represents a potential disease modifying therapeutic for ALSP Phase 1 data in healthy volunteers support entry into Phase 2 proof-of-concept trial in ALSP patients Emerging ILLUMINATE NHS data support exploring imagin
Slide 122: 2022–2023 Anticipated Milestones
2022–2023 Anticipated Milestones Initiate Phase 2 clinical trial with VGL101 in ALSP Announce topline data for Phase 1 clinical trial with VGL101 in healthy volunteers* Submit IND and initiate clinical development for small molecule TREM2 agonist Q4 2022 Q4 2022 2023 Establish Phase 2 proof of conce
Slide 123: Vigil is Well-positioned to Execute on Our Mission
Vigil is Well-positioned to Execute on Our Mission Our vision is a brighter tomorrow for people with devastating neurodegenerative diseases Microglial biology is rapidly becoming a new frontier for CNS drug discovery TREM2 deficiency leads to microglial dysfunction and drives neurodegeneration We ar
Slide 124: Q&A
Q&A VIGILANT FOR YOU is a registered trademark of Vigil Neuroscience, Inc. VIGIL, VIGIL NEUROSCIENCE, VIGIL NEURO, and the VIGIL NEURO logo are trademarks of Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2022. All rights reserved.
Slide 125: David S Lynch, MD, PhD
David S Lynch, MD, PhD Dr. David Lynch is a consultant neurologist at the National Hospital for Neurology & Neurosurgery at Queen Square, in London. His subspecialty interest is neurogenetics, with a particular focus on adult presentations of inherited white matter disorders (IWMD), also called leuk
Slide 126: Christina Sundal, MD, PhD
Christina Sundal, MD, PhD Dr. Sundal is the CEO of the Neuroclinic, Norway and an active lecturer in several neurological fields with emphasis on brain white matter disorders and unusual neurological diseases. She completed a research fellowship in the Parkinson’s Disease, Clinical Genomics and Move
Slide 127: Troy Lund, MSMS, PhD, MD, FAAP
Troy Lund, MSMS, PhD, MD, FAAP Dr. Troy Lund is an Associate Professor in the Department of Pediatrics, Division of Blood and Marrow Transplantation & Cellular Therapy and the Associate Director of the Metabolic Program at the University of Minnesota. He is an international expert on the use of cell
Vigil Neuroscience — Technical Presentation (December 2022) on 6ix